QualityStocksNewsBreaks Archives - Page 15 of 1449

ThursdayOct 09, 2025 9:10 am

QualityStocksNewsBreaks – Safe & Green Holdings Corp. (NASDAQ: SGBX) Regains Full Nasdaq Compliance and Strengthens Capital Structure

Safe & Green Holdings (NASDAQ: SGBX), a developer and designer of modular structures, announced it has regained compliance with all Nasdaq listing requirements, including Listing Rule 5550(a)(2) regarding the minimum $1.00 bid price. Nasdaq confirmed the matter closed as of Oct. 3, 2025. As part of its compliance plan, the Company restructured its agreement with Boral, cutting potential dilution by 80%, eliminating the Ace warrants, and resolving Nasdaq’s prior public interest concern related to potential share issuance. A subsequent reverse stock split reduced dilution by an additional 64%. CEO Mike McLaren said the milestone demonstrates Safe & Green’s commitment to…

ThursdayOct 09, 2025 9:00 am

QualityStocksNewsBreaks – Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) (FSE: P2QM) Expands Santa Barbara Mineralization with Robust Step-Out Drill Results

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) a mineral exploration company, reported additional assay results from step-out holes DSB-88 and DSB-89 in the Silver-Zinc-Polymetallic Domain of its Santa Barbara starter pit area at the Iska Iska Project, confirming continued mineralization open to the east. The results include 1.72% Zn over 456m in hole DSB-88 and 1.27% Zn, 24.51 g/t Ag, and 0.54% Pb over 154.50m in hole DSB-89, among the strongest intersections to date. CEO Tom Larsen said the drilling is expanding and upgrading resources ahead of the Preliminary Economic Assessment, while Executive VP Dr. Osvaldo Arce noted that…

ThursdayOct 09, 2025 9:00 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Files Provisional Patent to Strengthen Protection of AVERSA(TM) Abuse-Deterrent Technology

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the filing of a provisional patent application with the U.S. Patent and Trademark Office to expand protection for its AVERSA(TM) abuse-deterrent transdermal technology. The filing covers improved aversive formulations and coating application methods designed to enhance abuse deterrence and increase resistance to tampering. If converted to a non-provisional patent and granted, the new patent could extend AVERSA’s protection by up to 20 years from the filing date. AVERSA(TM) technology, already patented in 46 countries, incorporates aversive agents into transdermal patches to prevent misuse of drugs with abuse potential while…

WednesdayOct 08, 2025 3:18 pm

QualityStocksNewsBreaks – Platinum Group Metals Ltd. (NYSE American: PLG) (TSX: PTM) Set to Benefit Amid Strategic Metal Play

This article has been disseminated on behalf of Platinum Group Metals and may include a paid advertisement. Platinum Group Metals (NYSE American: PLG) (TSX: PTM) is focused on the development of the world-class platinum group metal Waterberg deposit in South Africa. “Platinum and palladium are quietly becoming important to modern defense technology. From hydrogen fuel cells in armored vehicles to high-performance electronics in advanced aircraft, militaries worldwide are turning to these critical metals to power the next generation of strategic systems. Platinum Group Metals is well positioned to benefit from this trend, advancing the high-quality Waterberg Project that promises a reliable supply…

WednesdayOct 08, 2025 2:38 pm

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) on the Beat of Cardiac Innovation

HeartBeam (NASDAQ: BEAT) is on the verge of revolutionizing cardiac diagnostics with its groundbreaking ECG technology. A recent article discussing this reads, “HeartBeam plans to initiate commercialization immediately upon receiving FDA clearance. The company’s vision is to empower patients and healthcare providers by offering a portable, cable-free ECG solution that combines clinical-grade accuracy with ease of use. This innovation is poised to reduce the burden on healthcare facilities, improve patient engagement, and increase the availability of high-quality cardiac monitoring, particularly in underserved areas or for patients requiring frequent arrhythmia assessments.” To view the full article, visit https://ibn.fm/kj3zb About HeartBeam Inc. HeartBeam is…

WednesdayOct 08, 2025 2:08 pm

QualityStocksNewsBreaks – NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Strengthens Pipeline with Dual Pathways for Ketamine-Based Therapies

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has re-filed an Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free intravenous (“IV”) ketamine formulation intended for all currently approved ketamine indications. This follows FDA approval of NRx’s Suitability Petition… KETAFREE(TM) is designed to eliminate benzethonium chloride (“BZT”), a known neurotoxic and cytotoxic preservative still present in many ketamine formulations. NRx previously submitted a Citizen Petition urging the FDA to ban BZT from all IV ketamine products, citing long-term health risks and filing supporting toxicology evidence… In parallel, NRx is advancing NRX-100, a separate preservative-free ketamine formulation, under a New Drug Application…

WednesdayOct 08, 2025 1:54 pm

QualityStocksNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Issues Q4 Shareholder Update Highlighting Cost Reductions, Healthcare Expansion, and Growth Across Core Channels

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels, issued a shareholder update detailing operational progress and strategic initiatives for the remainder of 2025. Interim CEO Charles M. Fernandez reported that the company has implemented a comprehensive restructuring plan focused on cost reduction, operational efficiency, and growth acceleration. Recent actions include realignment of NextPlat’s healthcare management team under Progressive Care’s new Vice President of Healthcare Operations, Birute Norkute, and the identification of approximately $2 million in annualized expense savings. The company also reported significant progress across its three…

WednesdayOct 08, 2025 11:55 am

QualityStocksNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Begins On-Site Validation at Planta Magdalena Project in Colombia

This article has been disseminated on behalf of ESGold and may include a paid advertisement. ESGold (CSE: ESAU) (OTCQB: ESAUF) announced that its geological and engineering team has arrived in Colombia to begin on-the-ground validation and due diligence at the Planta Magdalena Project, following the memorandum of understanding signed Aug. 20, 2025. The field program aims to confirm historic tailings grades, assess site infrastructure and throughput potential, and evaluate exploration opportunities across the Bolívar concession area. Bulk samples from both Colombia and Quebec have been shipped to ALS Global in Val-d’Or for metallurgical testing to verify gold and silver recoveries under…

WednesdayOct 08, 2025 10:36 am

QualityStocksNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Need for Advanced 3D Imaging During Breast Cancer Awareness Month

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing imaging-based technologies for more accurate breast cancer screening, diagnosis, and treatment, marked Breast Cancer Awareness Month by emphasizing the limitations of current imaging tools and the significant opportunity for its flagship IzoView Breast CT Imaging System. With more than 2.3 million new breast cancer cases reported globally each year—and over 315,000 expected in the U.S. in 2025—Izotropic underscored the urgent need for true high-resolution 3D imaging, especially for women with dense breast tissue, which affects roughly 50% of women and diminishes the accuracy of compression-based screening. As the…

WednesdayOct 08, 2025 10:16 am

QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Phase 1 Trial of Sapu-003, a Novel Intravenous Deciparticle(TM) Everolimus, Now Open for Enrollment in Australia

Oncotelic Therapeutics (OTCQB: OTLC), through its joint venture GMP Biotechnology Ltd. with Dragon Overseas Capital Ltd., announced that Sapu Nano presented its poster, “Sapu-003: Novel Intravenous Deciparticle(TM) Everolimus Entering Phase 1 Study in Australia,” at the 8th Australian Translational Breast Cancer Research Symposium (ATBCR 2025). The study marks the first clinical trial of an intravenous Deciparticle(TM) formulation of everolimus, an mTOR inhibitor used in breast cancer and other malignancies. Conducted in collaboration with SOCRU, Ingenū, and Medicilon, the trial (ACTRN12625001083482) is now enrolling patients with advanced HR+/HER2– breast cancer or other mTOR-sensitive tumors at leading oncology centers across Australia. “Sapu-003…

Site Search

Company Search

Category: QualityStocksNewsBreaks